Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France.

Taha MK, Hawkins JC, Liberator P, Deghmane AE, Andrew L, Hao L, Jones TR, McNeil LK, O'Neill RE, Perez JL, Jansen KU, Anderson AS.

Vaccine. 2017 Mar 13;35(11):1530-1537. doi: 10.1016/j.vaccine.2017.01.066. Epub 2017 Feb 10.

PMID:
28196734
2.

Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.

Creech CB, Frenck RW Jr, Sheldon EA, Seiden DJ, Kankam MK, Zito ET, Girgenti D, Severs JM, Immermann FW, McNeil LK, Cooper D, Jansen KU, Gruber W, Eiden J, Anderson AS, Baber J.

Vaccine. 2017 Jan 5;35(2):385-394. doi: 10.1016/j.vaccine.2016.11.032. Epub 2016 Nov 17.

3.

Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains.

Harris SL, Donald RG, Hawkins JC, Tan C, O'Neill R, McNeil LK, Perez JL, Anderson AS, Jansen KU, Jones TR.

Pediatr Infect Dis J. 2017 Feb;36(2):216-223. doi: 10.1097/INF.0000000000001399.

PMID:
27846061
4.

Approach to the Discovery, Development, and Evaluation of a Novel Neisseria meningitidis Serogroup B Vaccine.

Green LR, Eiden J, Hao L, Jones T, Perez J, McNeil LK, Jansen KU, Anderson AS.

Methods Mol Biol. 2016;1403:445-69. doi: 10.1007/978-1-4939-3387-7_25.

PMID:
27076147
5.

Demonstration of the preclinical correlate of protection for Staphylococcus aureus clumping factor A in a murine model of infection.

Scully IL, Timofeyeva Y, Keeney D, Matsuka YV, Severina E, McNeil LK, Nanra J, Hu G, Liberator PA, Jansen KU, Anderson AS.

Vaccine. 2015 Oct 5;33(41):5452-7. doi: 10.1016/j.vaccine.2015.08.029. Epub 2015 Aug 28.

6.

Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate Collections.

Jones CH, Mohamed N, Rojas E, Andrew L, Hoyos J, Hawkins JC, McNeil LK, Jiang Q, Mayer LW, Wang X, Gilca R, De Wals P, Pedneault L, Eiden J, Jansen KU, Anderson AS.

J Clin Microbiol. 2016 Jan;54(1):25-34. doi: 10.1128/JCM.01447-15. Epub 2015 Aug 26.

7.

IL-4 Knock Out Mice Display Anxiety-Like Behavior.

Moon ML, Joesting JJ, Blevins NA, Lawson MA, Gainey SJ, Towers AE, McNeil LK, Freund GG.

Behav Genet. 2015 Jul;45(4):451-60. doi: 10.1007/s10519-015-9714-x. Epub 2015 Mar 14.

8.

The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.

Zlotnick GW, Jones TR, Liberator P, Hao L, Harris S, McNeil LK, Zhu D, Perez J, Eiden J, Jansen KU, Anderson AS.

Hum Vaccin Immunother. 2015;11(1):5-13. doi: 10.4161/hv.34293. Epub 2014 Nov 1. Review.

9.

Mouse short- and long-term locomotor activity analyzed by video tracking software.

York JM, Blevins NA, McNeil LK, Freund GG.

J Vis Exp. 2013 Jun 20;(76). doi: 10.3791/50252.

10.

A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI).

McNeil LK, Price L, Britten CM, Jaimes M, Maecker H, Odunsi K, Matsuzaki J, Staats JS, Thorpe J, Yuan J, Janetzki S.

Cytometry A. 2013 Aug;83(8):728-38. doi: 10.1002/cyto.a.22319. Epub 2013 Jun 20.

11.

Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease.

McNeil LK, Zagursky RJ, Lin SL, Murphy E, Zlotnick GW, Hoiseth SK, Jansen KU, Anderson AS.

Microbiol Mol Biol Rev. 2013 Jun;77(2):234-52. doi: 10.1128/MMBR.00056-12. Review.

12.

Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in mice.

Johnson JE, McNeil LK, Megati S, Witko SE, Roopchand VS, Obregon JH, Illenberger DM, Kotash CS, Nowak RM, Braunstein E, Yurgelonis I, Jansen KU, Kalyan NK, Sidhu MK.

Immunol Lett. 2013 Feb;150(1-2):134-44. doi: 10.1016/j.imlet.2012.12.005. Epub 2012 Dec 20.

PMID:
23261719
13.

Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus.

Nanra JS, Buitrago SM, Crawford S, Ng J, Fink PS, Hawkins J, Scully IL, McNeil LK, Aste-Amézaga JM, Cooper D, Jansen KU, Anderson AS.

Hum Vaccin Immunother. 2013 Mar;9(3):480-7. Epub 2012 Dec 18.

14.

A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure.

Hawkins J, Kodali S, Matsuka YV, McNeil LK, Mininni T, Scully IL, Vernachio JH, Severina E, Girgenti D, Jansen KU, Anderson AS, Donald RG.

Clin Vaccine Immunol. 2012 Oct;19(10):1641-50. Epub 2012 Aug 15.

15.

Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis.

Anderson AS, Scully IL, Timofeyeva Y, Murphy E, McNeil LK, Mininni T, Nuñez L, Carriere M, Singer C, Dilts DA, Jansen KU.

J Infect Dis. 2012 Jun;205(11):1688-96. doi: 10.1093/infdis/jis272. Epub 2012 Apr 2.

16.

Macrophages make me sick: how macrophage activation states influence sickness behavior.

Moon ML, McNeil LK, Freund GG.

Psychoneuroendocrinology. 2011 Nov;36(10):1431-40. doi: 10.1016/j.psyneuen.2011.07.002. Epub 2011 Aug 19. Review.

17.

Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease.

Harris SL, Zhu D, Murphy E, McNeil LK, Wang X, Mayer LW, Harrison LH, Jansen KU, Anderson AS.

Hum Vaccin. 2011 Jan-Feb;7 Suppl:68-74. Epub 2011 Jan 1.

18.

Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage.

Ala'aldeen DA, Flint M, Oldfield NJ, Omer SA, McNeil LK, Jiang Q, Murphy E, Giardina PC, Novikova EG, Dodge-Scully IL, Bayliss CD, Turner DP, Neal KR, Hoiseth SK, Jansen KU, Anderson AS.

Vaccine. 2010 Nov 10;28(48):7667-75. doi: 10.1016/j.vaccine.2010.09.038. Epub 2010 Sep 25.

PMID:
20875489
19.

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.

Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, DaSilva I, Mack M, Zhao XJ, Pride MW, Andrew L, Murphy E, Hagen M, French R, Arora A, Jones TR, Jansen KU, Zlotnick GW, Anderson AS.

Vaccine. 2010 Aug 23;28(37):6086-93. doi: 10.1016/j.vaccine.2010.06.083. Epub 2010 Jul 7.

PMID:
20619376
20.

NMR dynamics and antibody recognition of the meningococcal lipidated outer membrane protein LP2086 in micellar solution.

Mascioni A, Moy FJ, McNeil LK, Murphy E, Bentley BE, Camarda R, Dilts DA, Fink PS, Gusarova V, Hoiseth SK, Malakian K, Mininni T, Novikova E, Lin S, Sigethy S, Zlotnick GW, Tsao DH.

Biochim Biophys Acta. 2010 Feb;1798(2):87-93. doi: 10.1016/j.bbamem.2009.09.021. Epub 2009 Oct 14.

Supplemental Content

Loading ...
Support Center